Table 2.

Distribution of EQ-5D dimensions as reported by patients (N = 416)

				Baseline			End of treatment			p value
				n	%		n	%
Mobility
	No problems Slight problems Moderate problems Severe problems Unable to walk about			323	78.59		364	88.35		< 0.001
				62	15.09		39	9.47
				20	4.87		9	2.18
				6	1.46		.	.
				.	.		.	.
Self-care
	No problems Slight problems Moderate problems Severe problems Unable to wash or dress			350	85.37		398	96.60		< 0.001
				52	12.68		11	2.67
				6	1.46		2	0.49
				2	0.49		1	0.49
				.	.		.	.
Usual activities
	No problems Slight problems Moderate problems Severe problems Unable to do usual activities			83	20.19		258	62.93		< 0.001
				161	39.17		111	27.07
				113	27.49		35	8.54
				50	12.17		6	1.46
				4	0.97		.	.
Pain / discomfort
	No problems Slight problems Moderate problems Severe problems Extreme pain or discomfort			93	22.63		206	50.00		< 0.001
				177	43.07		151	36.65
				113	27.49		45	10.92
				24	5.84		7	1.70
				4	0.97		3	0.73
Anxiety / depression
	No problems Slight problems Moderate problems Severe problems Extremely anxious or depressed			13	3.17		160	38.83		< 0.001
				106	25.85		187	44.39
				179	43.66		53	12.86
				105	25.61		11	2.67
				7	1.71		1	0.24

Note. Proportion of patients reporting the various levels of severity on the EQ-5D dimensions at baseline, and at end of treatment. The P-values denote significance of a non-parametric test of trends across ordered groups, developed by Cuzick, similar to the Wilcoxon rank-sum test [35]